Villanova Investment Management Co LLC Invests $1.51 Million in Lantheus Holdings, Inc. $LNTH

Villanova Investment Management Co LLC bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, HoldingsChannel reports. The firm bought 22,710 shares of the medical equipment provider’s stock, valued at approximately $1,511,000.

Other hedge funds also recently added to or reduced their stakes in the company. M&T Bank Corp acquired a new stake in Lantheus in the fourth quarter worth about $370,950,000. Farallon Capital Management LLC increased its holdings in shares of Lantheus by 56.1% during the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after acquiring an additional 1,950,252 shares in the last quarter. Norges Bank purchased a new position in shares of Lantheus in the 4th quarter valued at approximately $76,197,000. Freestone Grove Partners LP raised its position in shares of Lantheus by 4,114.8% in the 4th quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock valued at $40,497,000 after purchasing an additional 594,088 shares during the last quarter. Finally, Summit Street Capital Management LLC acquired a new stake in Lantheus in the 4th quarter worth approximately $26,997,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on LNTH. The Goldman Sachs Group reissued a “neutral” rating and set a $94.00 target price on shares of Lantheus in a research report on Thursday, May 7th. Mizuho raised their price target on shares of Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, May 27th. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Truist Financial reissued a “buy” rating and set a $115.00 price objective (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $110.00 target price on shares of Lantheus in a research report on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Stock Up 0.7%

Shares of LNTH stock opened at $103.92 on Friday. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $107.99. The stock has a market cap of $6.77 billion, a P/E ratio of 25.04 and a beta of -0.03. The stock has a 50 day moving average of $92.89 and a 200 day moving average of $78.06. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. The business had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 4.39 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.